B. Gülave

High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors

S. Teerenstra, L. Rodwell, B. Fabriek, 2021, ESMO open.